Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
about
Ranibizumab and bevacizumab for neovascular age-related macular degenerationVenous thromboembolic diseasePrevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsVenous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer AnticoagulantsPrimary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - ReviewBevacizumab for glioblastomaVenous thromboembolism and lung cancer: a reviewAnticoagulants in cancerHealth economic aspects of breast cancer treatment: the compulsory health insurances' viewIncidence and management of ZIv-aflibercept related toxicities in colorectal cancerValue of bevacizumab in treatment of colorectal cancer: A meta-analysisMedical management of brain tumors and the sequelae of treatment.Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR)Venous thromboembolism in the cancer population: pathology, risk, and preventionAngiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?What is the Best Treatment for a Cancer Patient with Thrombosis?Practical management of bevacizumab-related toxicities in glioblastomaReview of systemic therapies for locally advanced and metastatic rectal cancerRisk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysisPhase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinomaFive-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments TrialsSynthesis and antiangiogenic activity of N-alkylated levamisole derivativesFirst-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumorsIncreased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials.Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Venous thromboembolism in malignant gliomasOpportunities and challenges for successful use of bevacizumab in pediatrics.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapyDrug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Effect of intravitreal anti-vascular endothelial growth factor therapy on the risk of arterial thromboembolic events: a meta-analysisSafety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials.An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.Treating venous thromboembolism in patients with cancer.The therapeutic management of bleeding and thrombotic disorders complicating CNS malignancies.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.CalDAG-GEFI deficiency protects mice from FcγRIIa-mediated thrombotic thrombocytopenia induced by CD40L and β2GPI immune complexes
P2860
Q24616209-2401E329-6BA5-4F6F-BF8F-E3791EE661FEQ24631121-811EBEC7-177F-4DD6-B71D-8614762147E2Q24633010-F6800508-2325-4494-B28C-4E4DAFF0F1EAQ24633874-429F058E-9668-4CDB-8203-D72BF46C0457Q26741697-817B011C-0546-4813-8B0D-0E54F894C8A9Q26753853-7114CE58-BE52-479B-9755-DDE206BFB1BAQ26776307-18935D95-9173-449C-988F-8C7E801AB8E3Q26784184-ACC5AA79-1616-4FD7-BC4B-54092A67B892Q26825228-87C8A08D-2154-43F3-B066-41AAC7A0040EQ26826505-4F9F042E-35AC-433E-9D11-2D51773BB4A7Q26830219-06C5C330-B279-4F39-AB68-DB738A02BE05Q26849789-E1E574CA-CD62-487A-8C62-C3D30AC216D8Q26992174-6013C849-B03D-482F-AA19-B1772E608A7EQ26995284-6249173B-68EA-43E3-B2A3-AD9C7DFD38A6Q26996508-141B9F5F-559F-4698-B676-4382D5D44A8DQ27002538-53CD887C-50B8-4CBA-949F-1B3C9769E5B2Q27009514-0347CE04-03FD-48CF-9C4F-3745B8229203Q27015852-2176C75A-0800-477A-9646-E7BD42749A8FQ27021105-5CAEA1A6-02CE-4AE3-9E19-E0B0AF3B43A9Q27026453-D528B98B-8D6B-46ED-A367-B84F5891C355Q27851979-91E91AEA-3745-49FF-A7FF-9B86DF93A448Q28049700-6A896026-A35E-4365-808A-FCA88BC293BDQ28483795-4F93E152-46C8-4815-BC9B-B0F522C6B9ABQ28537681-4C4F803F-1CE7-40C5-9FF8-89926F10FCF6Q30248296-7E782CAA-9A44-4233-9FED-2D62FD52FAA3Q30417015-580C3DAD-C3E3-4276-B650-71809A370854Q30436810-E67BE936-3AF8-48B1-8A38-E548CED3A80CQ30454883-2824F4FB-0547-4073-A6B4-E154BF7C1FB8Q30455612-2A24F9DC-E031-4E59-ACA2-7CEA6542EFC4Q30616602-695BD61A-5B93-4FBE-9D52-D3EA428BA752Q30744946-B23D81F1-6B99-46F7-83C1-935B49A4E36AQ31060162-CFDFA8DC-E137-4E1F-B111-FC0A6F52DC6CQ31076710-F4CA30CB-B85F-44C8-B73E-DC0793ACC53FQ31127134-26B2F414-D0BD-48E4-BCCC-69BF85AB1118Q31152878-8661AFF3-CAE0-4F21-987E-401878ADE9E0Q33392652-81F1F39D-2A5F-421B-B468-376BF54F3935Q33400564-A70506AE-0A06-4A2A-8B6C-2D385786E2DCQ33402515-59E8AA69-EBFE-4804-9933-90B678FA8A11Q33408049-77706E00-700D-4A49-9592-B0DE60470DECQ33418006-71E80655-7254-476A-9F98-EFAEC7318595
P2860
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Risk of venous thromboembolism ...... cer patients: a meta-analysis.
@en
Risk of venous thromboembolism ...... cer patients: a meta-analysis.
@nl
type
label
Risk of venous thromboembolism ...... cer patients: a meta-analysis.
@en
Risk of venous thromboembolism ...... cer patients: a meta-analysis.
@nl
prefLabel
Risk of venous thromboembolism ...... cer patients: a meta-analysis.
@en
Risk of venous thromboembolism ...... cer patients: a meta-analysis.
@nl
P2093
P921
P356
P1476
Risk of venous thromboembolism ...... cer patients: a meta-analysis.
@en
P2093
Roger Keresztes
Shenhong Wu
Shobha Rani Nalluri
Xiaolei Zhu
P304
P356
10.1001/JAMA.2008.656
P407
P577
2008-11-01T00:00:00Z